Avandia Heart Attack Risk Greater Than Thought

Avandia, the popular GlaxoSmithKline’s diabetes’ drug, has been associated with a greater risk of heart attacks by a new study. Avandia had first been linked to cardiovascular side effects in 2007 when a Cleveland Clinic trial showed that those taking Avandia were at a 43% higher risk of experiencing cardiovascular problems.
“Given the accumulating evidence of harm with rosiglitazone (Avandia) therapy and the lack of a distinct clinical advantage for the drug over pioglitazone (Actos), it is reasonable to question whether ongoing use of rosiglitazone is justified in any circumstance,” noted the researchers in their study.